Navigation Links
Telik Announces New TRAP Drug Discovery Agreement
Date:11/12/2008

PALO ALTO, Calif., Nov. 12 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced today an agreement to provide its TRAP(R) drug discovery technology to investigators at the Hospital for Special Surgery (HSS). The Research Division of HSS studies the mechanisms underlying musculoskeletal and autoimmune diseases to discover effective treatments for these disorders. HSS investigators will use Telik's TRAP technology to discover novel compounds that inhibit a key enzyme in cell signaling and migration.

"By efficiently identifying novel small molecules that affect biological targets, Telik's TRAP technology offers a unique opportunity to accelerate our research," said Carl Blobel, M.D., Ph.D., Professor of Medicine, Physiology, and Biophysics, and Director of the Arthritis and Tissue Degeneration Program at HSS. "We are interested in membrane bound enzymes and the biological effects that result from their modulation. Rapidly finding small molecules that inhibit these enzymes could lead to new ways to treat diseases for which there is significant unmet medical need."

"This partnership allows the world-class investigators at HSS to leverage our recent advances in TRAP technology to accelerate the discovery of new therapeutics that target complex and novel biological targets," said Robert Lum, Ph.D., Telik's Vice President of Technology and Preclinical Development.

TRAP technology exploits the principle that drugs act by adhering to and interacting with cellular proteins. Telik has developed a novel computational approach to determine a molecular fingerprint for each of the over three million compounds in its library. TRAP technology uses these molecular fingerprints to rapidly search the library for promising lead molecules and to optimize these structures into new drug candidates.

About Telik

Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at http://www.telik.com.

Forward Looking Statements

This press release contains "forward-looking" statements, including statements regarding the potential application and capabilities of TRAP, and the potential utility of TRAP to HSS' drug discovery efforts. These forward-looking statements are based upon Telik's current expectations. There are important factors that could cause Telik's results to differ materially from those indicated by these forward-looking statements. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its quarterly report on Form 10-Q for the quarter ended September 30, 2008. Telik does not undertake any obligation to update forward-looking statements contained in this press release.

TELIK, the Telik logo, TELINTRA, TELCYTA, and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Telik Announces Financial Results for 2008 Third Quarter
2. Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer
3. Telik Announces 2008 Third Quarter Financial Release, Conference Call and Webcast
4. Telik Announces Receipt of Nasdaq Notice
5. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
6. ReceptorBio Announces Diabetes License Agreement With Telik
7. Telik Announces Financial Results For 2008 Second Quarter
8. Telik Announces 2008 Second Quarter Financial Release, Conference Call and Webcast
9. Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters
10. Telik Announces Presentation and Webcast at Needham Biotechnology Conference
11. Telik Announces First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... THOUSAND OAKS, Calif. , Dec. 2, 2016 ... AGN ) today announced the submission of a ... for ABP 215, a biosimilar candidate to Avastin ® ... biosimilar application submitted to the EMA. "The ... milestone as Amgen seeks to expand our oncology portfolio," said ...
(Date:12/2/2016)... -- Research and Markets has announced the addition ... Companies" to their offering. ... , , ... industries is anticipated. Nanotechnology will be applied at all stages ... diagnostic applications in clinical trials. Many of the assays based ...
(Date:12/2/2016)... , ... December 01, 2016 ... ... will share findings demonstrating the value of DNA microarray comparative genomic hybridization ... year’s San Antonio Breast Cancer Symposium. Using molecular test results from tumors ...
(Date:12/2/2016)... ... 01, 2016 , ... PhUSE will build on the huge ... Single Day Events (SDE) to organize a multiple-day US conference. The first annual ... of the pharmaceutical and life sciences industry will cover industry standards, data science, ...
Breaking Biology Technology:
(Date:11/29/2016)... VILNIUS, Lithuania , Nov. 29, 2016 ... high-precision biometric identification and object recognition technologies, ... kit (SDK) for fingerprint recognition solutions that ... extract a fingerprint template using less than ... used in compact devices that have limited ...
(Date:11/24/2016)... , Nov. 23, 2016 Cercacor today ... athletes and their trainers non-invasively measure hemoglobin, ... Pulse Rate, and Respiration Rate in approximately 30 seconds. ... users easy and immediate access to key data about ... of a training regimen. Hemoglobin carries ...
(Date:11/21/2016)... , Nov. 21, 2016   Neurotechnology ... object recognition technologies, today announced that the MegaMatcher ... cards was submitted for the NIST Minutiae ... passed all the mandatory steps of the evaluation ... is a continuing test of fingerprint templates used ...
Breaking Biology News(10 mins):